ZIVO Bioscience Initiates 42-Day Validation Study With Immune-Modulating Product For The Prevention And Treatment Of Coccidiosis In Broiler Chickens
Portfolio Pulse from Benzinga Newsdesk
ZIVO Bioscience, Inc. (NASDAQ:ZIVO) has initiated a 42-day study to validate the efficacy of its immune-modulating treatment for coccidiosis in broiler chickens. The product is designed to boost immune response, allowing birds to combat the disease without the use of antimicrobial compounds. The study aims to confirm the positive effects of ZIVO's non-antibiotic alternative, including reduced mortality and reduction in the incidence and severity of intestinal lesions. The results are expected by the end of 2023.
October 30, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ZIVO Bioscience's initiation of a 42-day study to validate its immune-modulating treatment for coccidiosis in broiler chickens could potentially boost its stock. The product, if successful, could transform poultry health management and reduce reliance on antibiotics.
The initiation of the study indicates progress in ZIVO's product development. If the study confirms the product's efficacy, it could lead to increased demand for ZIVO's product, potentially boosting its revenues and stock price. However, the results are expected by the end of 2023, so the impact may not be immediate.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100